BCRX ข่าวฟอเร็กซ์
BioCryst Pharma Receives Approval Of ORLADEYO From Public Health Institute Of Chile
BioCryst Pharmaceuticals, Inc. (BCRX) announced Monday that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.
RTTNews
|
620 วันที่ผ่านมา
BioCryst Says ORLADEYO Approved By Israeli Ministry Of Health To Prevent Hereditary Angioedema
BioCryst Pharmaceuticals, Inc. (BCRX) announced Monday that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel.
RTTNews
|
795 วันที่ผ่านมา
